Physicians are beginning to face patient questions about commercially available tests without definitive utility data to guide them.
In presentations at AACR, researchers discussed how drug sensitivity and other functional testing is improving precision oncology amid systemic barriers.
At AACR, the company highlighted new prospective and retrospective data that it believes helps set its platform apart from other available ctDNA technologies.
Lynparza, Ceralasertib Combo Trial Provides Clues on Biomarkers of Response in Pediatric Cancer
In the tumor-agnostic study, pediatric patients with 11q loss and other alterations associated with replication stress benefited from the dual PARP-ATR inhibitor treatment.
An analysis of whole-exome sequencing results presented at AACR suggests many people with hereditary cancer risk variants don't fall under current NCCN guidelines.